Politics

Tracking how politics and policy intersect with science and health care

Generic medicine bottle
Politics

Generic drug makers face ‘a silent crisis,’ FDA official says, and raising prices could help

By Ike Swetlitz

England Compounding Center
Politics

‘Stuff floating’ in compounded drugs prompts FDA to appeal for more funding

By Ike Swetlitz and Nicholas Florko

Greg Walden and Frank Pallone
Politics

AMA urges Congress not to loosen restrictions on privacy for patients with addiction history

By Lev Facher

generic drug
Politics

GOP lawmakers seeking to use opioids bill to deliver drug industry major victory

By Lev Facher and Nicholas Florko

Capitol Building
Politics

Top Trump health official calls on Congress to do more on drug pricing

By Ike Swetlitz

Politics

PBM lobbying group names a new president with deep Capitol Hill ties

By Nicholas Florko

Jerry Brown
Politics

Life sciences industry rallies behind Calif. bill to prevent a nightmare scenario for clinical research

By Rebecca Robbins

Thomas Goode
Special Report

Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies

By Caroline Chen and Riley Wong — ProPublica

California Rent Control Initiative
Politics

In unlikely alliance, PhRMA sides with landlords in Calif. referendum on rent control

By Lev Facher and Rebecca Robbins

Importing Marijuana
Politics

DEA approves importation of marijuana drug for tremor study

By Associated Press

BIRTH CONTROL
Health

Will insurers have to cover the controversial contraception app Natural Cycles under Obamacare’s mandate?

By Kate Sheridan

Mitch McConnell and Lamar Alexander
Politics

What’s in, what’s out, and what’s still on the table in the opioids package passed by the Senate

By Lev Facher

Pharmacy shelves
Politics

Senate passes bill to ban ‘gag clauses’ and free pharmacists to discuss drug pricing options

By Nicholas Florko

Fancy cocktails
Politics

In response to critic, NIH alcoholism institute changes online explanation of cancer risk from drinking

By Sharon Begley

Politics

Gottlieb pitches ‘subscriptions’ to incentivize pharma to make new antibiotics

By Ike Swetlitz

Stacy Cline Amin photo illustration
Politics

She’s been helping Republicans on Capitol Hill oversee the FDA for years. Now, she’ll be its top lawyer

By Ike Swetlitz

Richard Durbin & Chuck Grassley
Politics

The latest roadblock to Trump’s plan to put drug prices in ads: House Republicans

By Nicholas Florko

Wine toast
Health

Health researcher calls on NIH to retract statement about alcohol and cancer risk

By Sharon Begley

Dr. Scott Gottlieb,
Politics

A pharma exec raised the price of antibiotic by 400 percent — and the government can’t do much about it

By Ike Swetlitz and Nicholas Florko

Politics

Fact-checking an ad war over drug prices, Celgene, and Bob Hugin

By Damian Garde

FDA; Drug Administration campus
Politics

FDA official says Trump’s new limits on hiring foreign scientists makes it harder to attract top talent

By Ike Swetlitz

Bob Hugin - New Jersey Primary
Politics

The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

By Damian Garde

Carl H. June
Biotech

CAR-T pioneer on riding the NIH roller coaster, speaking up for science, and his funder Sean Parker

By Elizabeth Cooney

Kerri Evelyn Harris
Politics

Is mistrust of ‘big pharma’ enough to help unseat a Democratic stalwart in Congress?

By Lev Facher

AmerisourceBergen
Politics

A drug distributor flagged a pharmacy’s suspicious opioid orders. A federal court says it has to keep shipping the pills

By Lev Facher

CVS Miami
Pharmalot

CVS exec: Our new reliance on cost effectiveness should make drug makers ‘think about launch prices’

By Ed Silverman

Drug recovery center in Youngstown Ohio
Politics

The Senate could soon pass an opioids package. But a new law is still a long way away

By Lev Facher

Larry Kramer
Politics

At 83, AIDS activist Larry Kramer isn’t done ripping into his foes in pharma, FDA, and NIH

By Rick Berke

Exclusive

The Trump administration is starting to overhaul its guidelines for companies that make mail-order DNA

By Ike Swetlitz

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy